Immunohistochemistry examinations showed that BRCA1/2-mutated cancers have considerably higher numbers of CD3+ and CD8+ TILs and higher levels of PD-L1 and PD-1 expression in TILs compared to homologous recombination-proficient tumors [59]. This evidence concerns the gene PDCD1 and cancer.